RECRUITING

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older. Patients will undergo a medical and family history, physical examination, blood and urine tests. Additional tests and procedures may include the following: 1. X-rays 2. Consultations with specialists 3. DNA sample collection (blood or saliva sample) for genetic studies. These might include studies of specific genes, or more complete sequencing of the genome. 4. Additional blood samples a maximum of 1 pint (450 ml) during a 6-week period for studies of white cell adhesion (stickiness) 5. Leukapheresis for collecting larger amounts of white cells for study. For this procedure, whole blood is collected through a needle in an arm vein. The blood flows through a machine that separates it into its components. The white cells are removed and the rest of the blood is returned to the body through another needle in the other arm. Patients may be followed approximately every 6 months to monitor symptoms, adjust medicine dosages, and undergo routine blood and urine tests. They will receive genetic counseling by the study team on the risk of having affected children and be advised of treatment options. Participating relatives will undergo a medical and family history, possibly with a review of medical records, physical examination, blood and urine tests. Additional procedures may include a 24-hour urine collection, X-rays, and consultations with medical specialists. A DNA sample (blood or saliva) will also be collected for genetic studies. Additional blood samples of no more than 550 mL during an 8-week period may be requested for studies of white cell adhesion (stickiness). Relatives who have familial Mediterranean fever, TRAPS, or hyper-IgD syndrome will receive the same follow-up and counseling as described for patients above. Normal volunteers and patients with gout will have a brief health interview and check of vital signs (blood pressure and pulse) and will provide a blood sample (up to 90 ml, or 6 tablespoons). Additional blood samples of no more than 1 pint over a 6-week period may be requested in the future....

Official Title

An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases

Quick Facts

Study Start:1994-03-10
Study Completion:N/A
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00001373

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:2 Months to 115 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);
  2. 2. Regardless of gender, at least one month of age;
  3. 3. A medical history that, in the expert opinion of the study team, is consistent with the possibility of autoinflammatory disease; and
  4. 4. Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.
  5. 1. Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);
  6. 2. Regardless of gender, at least one month of age;
  7. 3. Relationship, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease;
  8. 4. Likelihood, in the expert opinion of the study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative s possible autoinflammatory condition; and
  9. 5. Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.
  10. 1. Stated willingness to participate in study procedures for healthy volunteers;
  11. 2. Regardless of gender, at least one year old, and not pregnant (by history of a missed menstrual period);
  12. 3. Likelihood, in the expert opinion of the study team, that a sample from the individual would advance the functional analysis of an autoinflammatory condition under study; and
  13. 4. Ability of the subject or parents (in the case of children) to understand and the willingness to sign a written informed consent document.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Amanda K Ombrello, M.D.
CONTACT
(301) 827-4258
ombrelloak@mail.nih.gov
Daniel L Kastner, M.D.
CONTACT
(301) 496-8364
kastnerd@mail.nih.gov

Principal Investigator

Daniel L Kastner, M.D.
PRINCIPAL_INVESTIGATOR
National Human Genome Research Institute (NHGRI)

Study Locations (Sites)

Childrens National Medical Center
Washington, District of Columbia, 20010
United States
Johns Hopkins University
Baltimore, Maryland, 21205
United States
Walter Reed National Medical Center
Bethesda, Maryland, 20301
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States
University of Pittsburgh
Pittsburgh, Pennsylvania, 15261
United States

Collaborators and Investigators

Sponsor: National Human Genome Research Institute (NHGRI)

  • Daniel L Kastner, M.D., PRINCIPAL_INVESTIGATOR, National Human Genome Research Institute (NHGRI)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date1994-03-10
Study Completion DateN/A

Study Record Updates

Study Start Date1994-03-10
Study Completion DateN/A

Terms related to this study

Keywords Provided by Researchers

  • Splenomegaly
  • Retinal Dystrophy
  • Periodic Fever
  • Optic Nerve Edema
  • HEADACHE
  • Genetics
  • Familial Mediterranean
  • Autoinflammation
  • Anhidrosis
  • Alpha-Kinase 1

Additional Relevant MeSH Terms

  • Familial Mediterranean Fever (FMF)
  • Autoinflammation
  • Periodic Fever
  • Fever
  • Genetic Diseases
  • ROSAH
  • ALPK1